Join BUHLMANN at AACC 2018

BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing

Health Canada License: 80726 US:  BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Quantum Blue® platform offering rapid and quantitative results for fecal calprotectinserum calprotectinCRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!)

Health Canada Licenses: Quantum Blue®  fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not for use in diagnostic procedures in the US

BÜHLMANN fCAL® turbo, the new high throughput, random access fecal calprotectin assay – unique in speed, quality, flexibility

Health Canada License: 96808 US: Research Use Only. Not for use in diagnostic procedures in the US

CALEX® Cap for rapid, clean, consistent and safe stool extraction

Health Canada License: 98839 US: Research Use Only. Not for use in diagnostic procedures in the US

Other Assays:

We offer a selection of unique, high-quality assays for Cellular Allergy testing such as the BÜHLMANN Flow CAST® product group  and numerous Allergens for Basophil Activation Testing and Neuroimmunology testing such as the BÜHLMANN GanglioCombi® products; the only screening ELISAs for anti-Ganglioside testing and Anti-MAG Autoantibodies ELISA. Other areas of BÜHLMANN’s focus include specialized niche products for Clinical Chemistry (ACE, GHB, etc.) as well as the first- to-market Chronobiology melatonin line of assays.

Because Accuracy is What Matters

An FDA-Cleared Gastrointestinal Test to Distinguish IBD from IBS

Calprotectin is a highly-sensitive clinical biomarker that has been shown to be extremely useful in the diagnosis and monitoring of inflammatory diseases in the gastrointestinal tract.

The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

This FDA 510k cleared, non-invasive, sensitive and specific assay is accurate, precise, efficient and offers reliable information to aid clinicians in selecting patients for further diagnostic procedures.

  • Robust: accurate, precise & efficient assay to instill confidence
  • Validated: in use worldwide providing over 1 million reliable patient results a year
  • Published: highly referenced, >75 peer reviewed scientific articles

Click & Contact AACC 2018 BUHLMANN Team

Connect with our team ahead of time, learn more about our assays or schedule a meeting!

Collin Shaw
Vice President, Business Development

Collin joined BDC in 2015 as the VP of Business Development. He has a MS in Cell Physiology, has been studying biomarkers in the medical diagnostics industry for 10+ years and has worked and published in the area of Diabetes, IBD, Cystic Fibrosis and neural pathobiology.

Jennifer Stuart
Technical Sales Specialist

Jennifer joined BDC as a Technical Sales Specialist in 2016, having spent 17 years performing Clinical Microbiology and Molecular Diagnostics in various hospital laboratory settings including MA General Hospital and Southern New Hampshire Medical Center. She is ASCP certified and received her BS in Medical Technology at the University of New Hampshire.